Latest Insider Transactions at Ani Pharmaceuticals Inc (ANIP)
This section provides a real-time view of insider transactions for Ani Pharmaceuticals Inc (ANIP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANI PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANI PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-2.55%
|
$48,552
$56.58 P/Share
|
|
Nov 15
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
6,500
-7.81%
|
$370,500
$57.7 P/Share
|
|
Nov 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$15,250
$61.36 P/Share
|
|
Oct 14
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,250
$57.19 P/Share
|
|
Sep 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,000
$56.82 P/Share
|
|
Sep 12
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,486
-2.88%
|
$83,216
$56.15 P/Share
|
|
Sep 08
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,646
-0.97%
|
$218,760
$60.51 P/Share
|
|
Aug 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,750
$59.62 P/Share
|
|
Jul 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
2,743
-0.43%
|
$170,066
$62.0 P/Share
|
|
Jul 18
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,743
-2.96%
|
$106,323
$61.35 P/Share
|
|
Jul 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
14,257
-2.19%
|
$898,191
$63.16 P/Share
|
|
Jul 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
22,000
-3.28%
|
$1,408,000
$64.27 P/Share
|
|
Jul 15
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
11,000
-1.61%
|
$693,000
$63.38 P/Share
|
|
Jul 12
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,000
$64.91 P/Share
|
|
Jul 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-9.38%
|
$1,260,000
$63.44 P/Share
|
|
Jun 21
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
20,000
-2.85%
|
$1,160,000
$58.9 P/Share
|
|
Jun 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
11,447
-1.6%
|
$675,373
$59.86 P/Share
|
|
Jun 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,607
-1.46%
|
$636,420
$60.76 P/Share
|
|
Jun 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
7,946
-1.08%
|
$484,706
$61.41 P/Share
|
|
Jun 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$15,750
$63.8 P/Share
|
|
Jun 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
11,087
-8.6%
|
$742,829
$67.7 P/Share
|
|
Jun 07
2024
|
James G. Marken SVP OPS & PROD DEV |
BUY
Exercise of conversion of derivative security
|
Direct |
12,550
+4.74%
|
$665,150
$53.29 P/Share
|
|
Jun 05
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
2,985
-3.72%
|
$199,995
$67.0 P/Share
|
|
Jun 04
2024
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
5,000
-2.99%
|
$315,000
$63.58 P/Share
|
|
Jun 03
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-8.58%
|
$1,280,000
$64.41 P/Share
|
|
May 21
2024
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+9.8%
|
-
|
|
May 21
2024
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+5.57%
|
-
|
|
May 21
2024
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+12.44%
|
-
|
|
May 21
2024
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+16.31%
|
-
|
|
May 21
2024
|
Matthew J Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+26.89%
|
-
|
|
May 21
2024
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+7.88%
|
-
|
|
May 21
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
2,000
-2.35%
|
$122,000
$61.61 P/Share
|
|
May 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
12,855
-1.72%
|
$784,155
$61.81 P/Share
|
|
May 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,836
-0.78%
|
$361,832
$62.09 P/Share
|
|
May 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
16,459
-2.14%
|
$1,036,917
$63.84 P/Share
|
|
May 16
2024
|
Renee P Tannenbaum Director |
SELL
Open market or private sale
|
Direct |
2,000
-9.9%
|
$126,000
$63.87 P/Share
|
|
May 15
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
14,850
-1.9%
|
$965,250
$65.86 P/Share
|
|
May 14
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
16,669
-4.23%
|
$1,100,154
$66.1 P/Share
|
|
May 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,750
$67.69 P/Share
|
|
May 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-7.9%
|
$1,320,000
$66.62 P/Share
|
|
Apr 19
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
16,809
-2.1%
|
$1,092,585
$65.17 P/Share
|
|
Apr 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,423
-1.29%
|
$667,072
$64.98 P/Share
|
|
Apr 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
9,520
-1.16%
|
$618,800
$65.4 P/Share
|
|
Apr 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,834
-0.71%
|
$385,044
$66.2 P/Share
|
|
Apr 15
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
7,414
-0.89%
|
$489,324
$66.33 P/Share
|
|
Apr 12
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,750
$67.79 P/Share
|
|
Apr 10
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-2.64%
|
$299,244
$66.96 P/Share
|
|
Apr 10
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,799
-2.36%
|
$184,734
$66.96 P/Share
|
|
Apr 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-7.32%
|
$1,340,000
$67.25 P/Share
|
|
Mar 23
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-3.49%
|
$428,490
$69.58 P/Share
|